Imcheck Therapeutics
French tech company | Builders Republic
About
Clinical-stage biotech developing first-in-class immunotherapeutic antibodies targeting the butyrophilin (BTN/BTNL) checkpoint superfamily — lead program ICT01 (anti-BTN3A mAb) activates gamma-delta T cells against cancer; pipeline covers hematological malignancies and autoimmune disease.
Key facts
- Status
- Rachetée
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series C
- Founded
- 2015
- City
- MARSEILLE
- Region
- Provence-Alpes-Côte d’Azur
- Legal name
- IMCHECK THERAPEUTICS
- SIREN
- 812428142
- Tracked rounds
- 1
- Amount raised
- 96 M€ raised since 2020
Funding rounds
- Series C — 2022
Investors
- Agent Capitalpfizer Ventures
- Alexandria Venture Investments
- Boehringer Ingelheim Venture Fund
- bpifrance
- Earlybird Venture Capital
- EQT Lifesciences
- Eurazeo
- Gimv
- Kurma Partners
- Pureos Bioventures
Notes
Rachetée par Ipsen (accord annoncé octobre 2025).